Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sino BiopharmaceuticalSBMFF 63 Debt-to-EBITDA is 7.10 as of Dec. 2025, which is 450% above its 10-year median of 1.29. GuruFocus rates SBMFF with a GF Score™ of 63/100 and a GF Value™ of $0.67 (Fairly Valued). The stock has 4 warning signs investors should review. Among 298 Biotechnology companies, Sino Biopharmaceutical ranks worse than 61.07% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Sino Biopharmaceutical's Debt-to-EBITDA or its related term are showing as below:
SBMFF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.27 Med: 1.29 Max: 2.25
Current: 2.25
During the past 13 years, the highest Debt-to-EBITDA Ratio of Sino Biopharmaceutical was 2.25. The lowest was 0.27. And the median was 1.29.
SBMFF's Debt-to-EBITDA is ranked worse than 61.07% of 298
companies
in the Biotechnology industry
Industry Median: 1.15
vs SBMFF: 2.25
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Sino Biopharmaceutical Debt-to-EBITDA Related Terms
Sino Biopharmaceutical Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Sino Biopharmaceutical's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SBMFF vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Sino Biopharmaceutical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sino Biopharmaceutical Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sino Biopharmaceutical's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Sino Biopharmaceutical (SBMFF) has a Debt-to-EBITDA of 7.10 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sino Biopharmaceutical. This is 450% above median its historical median of 1.29. Over the past decade, Sino Biopharmaceutical's Debt-to-EBITDA has ranged from 0.27 to 2.25. According to the industry distribution chart, Sino Biopharmaceutical ranks #182 out of 298 companies in the Biotechnology industry, placing it in the top 61.1%.
Is Sino Biopharmaceutical's Debt-to-EBITDA too high?
Sino Biopharmaceutical's current Debt-to-EBITDA of 7.10 is 450% above median its 10-year median of 1.29. Over the past 10 years, this metric has ranged from a low of 0.27 to a high of 2.25. The Biotechnology industry median Debt-to-EBITDA is 1.15. Sino Biopharmaceutical's value of 7.10 is 517.4% above this industry median. Based on the distribution chart, Sino Biopharmaceutical ranks #182 out of 298 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sino Biopharmaceutical has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sino Biopharmaceutical ranks #182 out of 298 companies for Debt-to-EBITDA. This places Sino Biopharmaceutical in the lower half of its industry. The industry median Debt-to-EBITDA is 1.15. Sino Biopharmaceutical's value of 7.10 is 517.4% above this benchmark. Historically, Sino Biopharmaceutical's own Debt-to-EBITDA has ranged from 0.27 to 2.25 over the past decade. While the company's 10-year median is 1.29 vs. the industry median of 1.15, Sino Biopharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.15, based on 298 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sino Biopharmaceutical's current Debt-to-EBITDA of 7.10 is 517.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sino Biopharmaceutical. For the Biotechnology industry, the median Debt-to-EBITDA is 1.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sino Biopharmaceutical's current Debt-to-EBITDA is 7.10, which is 450% above median its own 10-year median of 1.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Fairly Valued. The stock's GF Value™ is $0.67, compared to a current price of $0.61 — trading 9% below its estimated fair value. The current Debt-to-EBITDA is 7.10, which is 450% above median its 10-year median of 1.29 and 517.4% above the Biotechnology industry median of 1.15. Sino Biopharmaceutical's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current Debt-to-EBITDA is 7.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?
Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be undervalued.
The current stock price of $0.61 is trading 9% below its estimated GF Value™ of $0.67.
GuruFocus considers Sino Biopharmaceutical to be Fairly Valued.
Key valuation signals for SBMFF:
Debt-to-EBITDA: 7.10 (450% above median its 10-year median of 1.29)
GF Value™: $0.67 vs. price of $0.61 (9% below fair value)
Industry Position: 517.4% above the Biotechnology median (#182 of 298)
No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
63GF Score
Get the complete analysis for SBMFF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBMFF has been successfully added to your 
